Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

SIMPLE SUMMARY: Deficient Mismatch Repair (dMMR) is an oncogenic path accounting for around 15% of cancers. It is considered as the first predictive marker of efficacy for immune checkpoint inhibitors (ICI). However, around 39% of cases are refractory and additional biomarkers are needed. The Lung I...

Descripción completa

Detalles Bibliográficos
Autores principales: Auclin, Edouard, Vuagnat, Perrine, Smolenschi, Cristina, Taieb, Julien, Adeva, Jorge, Nebot-Bral, Laetitia, Garcia de Herreros, Marta, Vidal Tocino, Rosario, Longo-Muñoz, Federico, El Dakdouki, Yola, Martín-Romano, Patricia, Gaba, Lydia, Saurí, Tamara, Oliveres, Helena, Castañón, Eduardo, Garcia-Carbonero, Rocio, Besse, Benjamin, Massard, Christophe, Mezquita, Laura, Hollebecque, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345164/
https://www.ncbi.nlm.nih.gov/pubmed/34359675
http://dx.doi.org/10.3390/cancers13153776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345164/
https://www.ncbi.nlm.nih.gov/pubmed/34359675
http://dx.doi.org/10.3390/cancers13153776

Ejemplares similares